<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diazoxide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diazoxide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diazoxide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9346" href="/d/html/9346.html" rel="external">see "Diazoxide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11935" href="/d/html/11935.html" rel="external">see "Diazoxide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F159130"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Proglycem</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866577"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Proglycem</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052188"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypoglycemic Agent</span>;</li>
<li>
<span class="list-set-name">Vasodilator</span></li></ul></div>
<div class="block don drugH1Div" id="F53462425"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d5194e-45b7-43a0-9b24-74654387d9c8">Hyperinsulinemic hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperinsulinemic hypoglycemia </b>
<b>(eg, congenital hyperinsulinism [HI], perinatal stress-induced HI):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pulmonary hypertension has been observed in neonates while on diazoxide therapy; most frequently reported at doses ≥10 mg/kg/day; monitor neonates closely while on therapy; prior to initiation, all patients should have a thorough cardiac evaluation and consideration of baseline and periodic echocardiogram (Brar 2020; Timlin 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Oral: 3 to 15 mg/kg/day in divided doses every 8 to 12 hours; initiate at the low end of dose range to minimize adverse effects, especially in patients with underlying cardiac disease or if perinatal stress-induced HI is suspected. In patients with perinatal stress-induced HI, consider avoiding the use of diazoxide until after 7 to 10 days of life if euglycemia can be maintained by other means (Balachandran 2018; Brar 2020; Chandran 2022; Hoe 2006; Hussain 2004). Gradually titrate dose as needed to maintain serum glucose concentrations &gt;70 mg/dL; use the lowest effective dose to minimize adverse effects; doses &gt;15 mg/kg/day should be avoided (Brar 2020). Due to the long half-life, it may take at least 5 days to assess dose response (Barrero-Castillero 2022; Brar 2020). The manufacturer recommends discontinuing if no effect is seen after 2 to 3 weeks. If transient HI is suspected, the dose of diazoxide may be reduced every 2 to 4 weeks if glucose levels are stable (&gt;70 mg/dL) (Brar 2020). <b>Note:</b> Strongly consider use in combination with a thiazide diuretic to minimize fluid retention (Brar 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing: Altered Kidney Function: Neonatal:</b> There are no dosage adjustments provided in the manufacturer's labeling. Half-life may be prolonged with renal impairment; a reduced dose may be necessary. Use with caution and monitor blood glucose and fluid status closely.</p></div>
<div class="block dop drugH1Div" id="F159147"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d5194e-45b7-43a0-9b24-74654387d9c8">Hyperinsulinemic hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperinsulinemic hypoglycemia: Note:</b> Diazoxide may not be effective for all types of hyperinsulinemic hypoglycemia. Dose should be individualized and may vary based on the cause (eg, genetic mutation, insulinomas) and severity of the hypoglycemic condition, blood glucose concentration, and clinical response of patient. Use the least amount of drug that achieves the desired clinical and laboratory results. For some hyperinsulinemic conditions, onset of action may vary; the manufacturer recommends discontinuation if no effect after 2 to 3 weeks; however, this may vary based on condition being treated and this timeframe. Often used in combination with a thiazide diuretic to ameliorate possible fluid retention that may occur with diazoxide therapy (Shah 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: Initial: 5 mg/kg/day in divided doses every 8 hours; gradually titrate; due to the long half-life it may take several days (eg, 5 days) to assess dose-response (Eichenwald 2017); usual range: 8 to 15 mg/kg/day in divided doses every 8 to 12 hours; reported range: 5 to 20 mg/kg/day in divided doses every 8 to 12 hours (Demirbilek 2017; Kapoor 2009; Shah 2017). <b>Note:</b> Pulmonary hypertension has been observed in neonates and infants while on diazoxide therapy; most frequently reported at doses ≥10 mg/kg/day; monitor neonates and infants closely while on therapy; consider baseline and periodic echocardiogram (Timlin 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 5 mg/kg/day in divided doses every 8 hours; reported range: 5 to 20 mg/kg/day in divided doses every 8 to 12 hours; usual range: 3 to 8 mg/kg/day in divided doses every 8 to 12 hours (Demirbilek 2017; Shah 2017; Sperling 2014).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109215"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: Half-life may be prolonged with renal impairment; a reduced dose should be considered.</p></div>
<div class="block dohp drugH1Div" id="F51109216"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F159135"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9346" href="/d/html/9346.html" rel="external">see "Diazoxide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d5194e-45b7-43a0-9b24-74654387d9c8">Hyperinsulinemic hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperinsulinemic hypoglycemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use when other specific medical therapy or surgical management for hypoglycemia is unsuccessful or is not feasible.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 3 mg/kg/day divided into 3 equal doses every 8 hours; dosing range: 3 to 8 mg/kg/day divided into 2 or 3 equal doses every 8 to 12 hours. Adjust dose until the desired clinical and laboratory effects are produced. <b>Note:</b> Patients with refractory hypoglycemia may require higher doses. Discontinue if no effect after 2 to 3 weeks.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990170"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; consider a dosage reduction (half-life may be prolonged).</p></div>
<div class="block doha drugH1Div" id="F50987514"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F159102"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (transient), hypotension, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous candidiasis, loss of scalp hair, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, diabetes mellitus with hyperosmolar coma (nonketotic), diabetic ketoacidosis, fluid retention, galactorrhea not associated with childbirth, hirsutism, hyperglycemia, increased uric acid, sodium retention</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, acute pancreatitis, ageusia (transient), anorexia, diarrhea, intestinal obstruction, nausea, pancreatic necrosis, vomiting</p>
<p style="text-indent:0em;margin-left:2em;">Genitourinary: Azotemia, decreased urine output, glycosuria, hematuria, lump in breast (enlargement)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, decreased serum immunoglobulins (IgG), eosinophilia, hemorrhage (excessive), lymphadenopathy, neutropenia (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, dizziness, extrapyramidal reaction, headache, insomnia, malaise, paresthesia, peripheral neuritis (poly)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Accelerated bone maturation, gout</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cataract (transient), diplopia, lacrimation, scotoma (ring), subconjunctival hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, nephrotic syndrome (reversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, pericardial effusion (Avatapalle 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hypertrichosis (Salido 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Necrotizing enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolysis (Best 1975), immune thrombocytopenia (Thus 2019), thrombocytopenia (Adachi 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary hypertension (infants and neonates) (Ohnishi 2020)</p></div>
<div class="block coi drugH1Div" id="F159117"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to diazoxide, other thiazides, or any component of the formulation; functional hypoglycemia</p></div>
<div class="block war drugH1Div" id="F159099"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abnormal facial features: Development of abnormal facial features was reported in children treated &gt;4 years for hypoglycemia hyperinsulinism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemic crises: Ketoacidosis or hyperosmolar coma may occur during treatment; usually in patients with concomitant illness; prompt recognition and treatment are essential.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use may lead to increased fluid retention due to antidiuretic properties and may precipitate heart failure in patients with compromised cardiac reserve.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: Use with caution in patients with hyperuricemia or a history of gout.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May displace bilirubin from albumin; use caution in newborns with hyperbilirubinemia. Pulmonary hypertension has been reported in newborns and young infants and was reversible upon drug discontinuation; monitor patients (especially patients with risk factors for pulmonary hypertension) for respiratory distress and discontinue diazoxide if pulmonary hypertension is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878422"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Initiate treatment with diazoxide under close clinical supervision; carefully monitor blood glucose and clinical response until patient's condition becomes stable (usually several days). Regular monitoring of urine for glucose and ketones (especially under conditions of stress) are required with prolonged therapy; abnormal results should be reported to physician promptly. Periodic monitoring of blood glucose is required for dosage adjustment.</p>
<p style="text-indent:0em;margin-top:2em;">Pulmonary hypertension has been reported in newborns and infants receiving diazoxide for hypoglycemia; since the early 1970’s, eleven cases have been reported either to the FDA or within the literature; in the majority of cases, the neonate/infant had other ongoing serious medical conditions and were at high risk for development of pulmonary hypertension; reported onset was within a day to a few months after diazoxide therapy initiation and in all cases, the pulmonary hypertension resolved or improved with discontinuation of the diazoxide. Pulmonary hypertension may be dose dependent; a review of published cases reported that circulatory effects were observed most frequently at doses ≥10 mg/kg/day. Monitor neonates and infants closely for signs of respiratory distress (tachypnea, flaring nostrils, grunting, chest wall retractions), cyanosis, or feeding intolerance, particularly those neonates and infants with risk factors for pulmonary hypertension (eg, meconium aspiration syndrome, respiratory distress syndrome, transient tachypnea of the newborn, pneumonia, sepsis, congenital diaphragmatic hernia, congenital heart disease); discontinue if pulmonary hypertension is identified (FDA 2015; Timlin 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Transient cataracts have been reported in an infant in association with hyperosmolar coma; cataracts subsided following correction of hyperosmolarity. Abnormal facial features have been reported in 4 children who received diazoxide for &gt;4 years for the treatment of hypoglycemia hyperinsulinism.</p>
<p style="text-indent:0em;margin-top:2em;">The oral suspension contains 7.25% alcohol. Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F159111"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proglycem: 50 mg/mL (30 mL) [chocolate mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (30 mL)</p></div>
<div class="block geq drugH1Div" id="F159095"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F159119"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Diazoxide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $12.38 - $12.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Proglycem Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $17.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866578"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proglycem: 100 mg</p></div>
<div class="block admp drugH1Div" id="F52612538"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Shake suspension well before each use; suspension comes with calibrated dropper (to deliver dose of 10 to 50 mg, in 10 mg increments).</p></div>
<div class="block adm drugH1Div" id="F45613354"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Shake suspension well before each use.</p></div>
<div class="block sts drugH1Div" id="F159126"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Store in carton until contents are used. </p></div>
<div class="block usep drugH1Div" id="F53566464"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Management of hypoglycemia related to hyperinsulinism secondary to the following conditions: Islet cell adenoma, adenomatosis, or hyperplasia; extrapancreatic malignancy; nesidioblastosis; leucine sensitivity (All indications: FDA approved in neonates, infants, and children)</p>
<p style="text-indent:-2em;margin-left:2em;">Management of hypoglycemia related to hyperinsulinism secondary to the following conditions: Inoperable islet cell adenoma or carcinoma; extrapancreatic malignancy (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F159165"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diazoxide may be confused with diazePAM, Dyazide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299180"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F159104"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Diazoxide may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Diazoxide may decrease the serum concentration of Fosphenytoin-Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of Diazoxide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: May enhance the hypotensive effect of Diazoxide.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5636010"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Diazoxide crosses the human placenta and appears in cord blood. Altered carbohydrate metabolism, hyperbilirubinemia, and thrombocytopenia have been reported in the fetus or neonate. Alopecia and hypertrichosis lanuginosa have also been reported in infants following maternal use of diazoxide during the last 19 to 60 days of pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53566418"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood glucose, electrolytes, renal function (BUN, SCr); AST; CBC with differential and platelets (baseline, 5 to 7 days after initiation, then every 3 to 6 months thereafter) (Brar 2020); serum uric acid (baseline, 5 to 7 days after initiation, then every 6 months thereafter) (Brar 2020); urine glucose and ketones (baseline, during therapy initiation, and then periodically); blood pressure (especially with IV therapy), heart rate; signs of fluid overload, pulmonary hypertension, and respiratory decompensation (neonates/infants [eg, respiratory, cyanosis, feeding intolerance]); consider echocardiogram in neonates and infants (baseline, 5 to 7 days after initiation, and periodically) (Brar 2020; Timlin 2017); signs of feeding intolerance.</p></div>
<div class="block pha drugH1Div" id="F159098"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Opens ATP-dependent potassium channels on pancreatic beta cells in the presence of ATP and Mg<sup>2+</sup>, resulting in hyperpolarization of the cell and inhibition of insulin release. Diazoxide binds to a different site on the potassium channel than the sulfonylureas (Doyle 2003).</p></div>
<div class="block phk drugH1Div" id="F159116"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hyperglycemic: Oral: Within 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Hyperglycemic: Oral: Normal renal function: ≤8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: 5.9 to 27.7 hours (Kizu 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 24 to 36 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51221004"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038599"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat | Proglycem</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Azoxid | Proglycem | Upglycem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hypertonalum | Proglicem</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Proglicem | Proglycem</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diapressin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat | Proglicem</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eudemine | Eudemine glx</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Proglycem</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Proglycem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat | Proglicem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aroglycem</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Proglycem</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Diazoxido | Hiterdol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eudemine | Hyperstat | Hypertonalum | Proglycem</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hyperstat | Proglycem</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Diapressin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Proglicem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Adachi J, Mimura M, Minami I, Kakihana K, Watanabe T. Thrombocytopenia induced by diazoxide in a patient with an insulinoma. <i>Intern Med</i>. 2014;53(7):759-762. doi:10.2169/internalmedicine.53.1094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22761225">
<a name="22761225"></a>Avatapalle B, Banerjee I, Malaiya N, Padidela R. Echocardiography monitoring for diazoxide induced pericardial effusion. <i>BMJ Case Rep</i>. 2012;2012:bcr0320126110. doi:10.1136/bcr.03.2012.6110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/22761225/pubmed" id="22761225" target="_blank">22761225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385640">
<a name="29385640"></a>Balachandran B, Mukhopadhyay K, Sachdeva N, Walia R, Attri SV. Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects. <i>Acta Paediatr</i>. 2018;107(6):990-995. doi:10.1111/apa.14252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/29385640/pubmed" id="29385640" target="_blank">29385640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barrero-Castillero.1">
<a name="Barrero-Castillero.1"></a>Barrero-Castillero A, Simmons R. Hypoglycemia and hyperglycemia. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022: chap. 24.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1215255">
<a name="1215255"></a>Best RA, Clink HM. Haemolysis associated with diazoxide, used for the control of hypertension. <i>Postgrad Med J</i>. 1975;51(596):402-404. doi:10.1136/pgmj.51.596.402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/1215255/pubmed" id="1215255" target="_blank">1215255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32810255">
<a name="32810255"></a>Brar PC, Heksch R, Cossen K, et al. Management and appropriate use of diazoxide in infants and children with hyperinsulinism. <i>J Clin Endocrinol Metab</i>. 2020;105(12):dgaa543. doi:10.1210/clinem/dgaa543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/32810255/pubmed" id="32810255" target="_blank">32810255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34544689">
<a name="34544689"></a>Chandran S, R PR, Mei Chien C, Saffari SE, Rajadurai VS, Yap F. Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2022;107(4):359-363. doi:10.1136/archdischild-2021-322845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/34544689/pubmed" id="34544689" target="_blank">34544689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28855921">
<a name="28855921"></a>Demirbilek H, Rahman SA, Buyukyilmaz GG, Hussain K. Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology. <i>Int J Pediatr Endocrinol</i>. 2017;2017:9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/28855921/pubmed" id="28855921" target="_blank">28855921</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Diazoxide oral suspension [prescribing information]. Boca Raton, FL: e5 Pharma LLC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12615955">
<a name="12615955"></a>Doyle ME and Egan JM, “Pharmacological Agents That Directly Modulate Insulin Secretion,” <i>Pharmacol Rev</i>, 2003, 55(1):105-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/12615955/pubmed" id="12615955" target="_blank">12615955</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2015">
<a name="FDA.2015"></a>FDA Safety Alert. Proglycem (diazoxide). Food and Drug Administration Website. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor Human MedicalProducts/ucm455125.htm</a> Accessed July 16, 2015.</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide). Available at <a href="http://www.fda.gov/Drugs/DrugSafety/ucm454833.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm454833.htm</a>. Last accessed July 20, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16492430">
<a name="16492430"></a>Hoe FM, Thornton PS, Wanner LA, Steinkrauss L, Simmons RA, Stanley CA. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. <i>J Pediatr</i>. 2006;148(2):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/16492430/pubmed" id="16492430" target="_blank">16492430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711860">
<a name="14711860"></a>Hussain K and Aynsley-Green A. Hyperinsulinaemic hypoglycaemia in preterm neonates. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2004;89(1):F65-F67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/14711860/pubmed" id="14711860" target="_blank">14711860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193661">
<a name="19193661"></a>Kapoor RR, Flanagan SE, James C, et al. Hyperinsulinaemic hypoglycaemia. <i>Arch Dis Child</i>. 2009;94(6):450-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/19193661/pubmed" id="19193661" target="_blank">19193661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28715810">
<a name="28715810"></a>Kizu R, Nishimura K, Sato R, et al. Population pharmacokinetics of diazoxide in children with hyperinsulinemic hypoglycemia. <i>Horm Res Paediatr</i>. 2017;88(5):316-323. doi:10.1159/000478696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/28715810/pubmed" id="28715810" target="_blank">28715810</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lancaster-Smith M, Leigh NI, and Thompson HM, “Death Following Non-ketotic Hyperglycemic Coma During Diazoxide Therapy and Peritoneal Dialysis,” <i>Postgrad Med J</i>, 1974, 50(581):175-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32921661">
<a name="32921661"></a>Ohnishi Y, Okada S, Yasudo H, Kimura S, Suzuki Y, Hasegawa S. Pulmonary hypertension following increased dosing of diazoxide in an infant. <i>Int Heart J</i>. 2020;61(5):1084-1087. doi:10.1536/ihj.20-024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/32921661/pubmed" id="32921661" target="_blank">32921661</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Proglycem (diazoxide) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; December 2020.</div>
</li>
<li>
<div class="reference">
                  Proglycem (diazoxide) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; December 2022.</div>
</li>
<li>
<div class="reference">
                  Proglycem (diazoxide) [prescribing information]. North Wales, PA: Teva; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22989667">
<a name="22989667"></a>Salido R, Gómez-García FJ, Garnacho-Saucedo G, Galán-Gutiérrez M. Acquired generalized hypertrichosis due to diazoxide. <i>Actas Dermosifiliogr</i>. 2013;104(2):166-167. doi:10.1016/j.ad.2012.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/22989667/pubmed" id="22989667" target="_blank">22989667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27915035">
<a name="27915035"></a>Shah P, Rahman SA, Demirbilek H, Güemes M, Hussain K. Hyperinsulinaemic hypoglycaemia in children and adults. <i>Lancet Diabetes Endocrinol</i>. 2017;5(9):729-742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/27915035/pubmed" id="27915035" target="_blank">27915035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Philadelphia, PA: Elsevier Saunders; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511269">
<a name="31511269"></a>Thus KA, den Boogert WJ, van der Heyden JC. Thrombocytopaenia: a serious side effect of diazoxide. <i>BMJ Case Rep</i>. 2019;12(9):e231222. doi:10.1136/bcr-2019-231222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/31511269/pubmed" id="31511269" target="_blank">31511269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28642988">
<a name="28642988"></a>Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. <i>Pediatr Cardiol</i>. 2017;38(6):1247-1250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/28642988/pubmed" id="28642988" target="_blank">28642988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diazoxide-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13224 Version 168.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
